RCM
DRUG

RA Capital Management’s Bright Minds Biosciences DRUG Stock Holding History

RA Capital Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.6M Hold
265,000
– – 0.16% 64
2026
Q1 		$19.3M Buy
+265,000
New +$21.3M 0.2% 60
2025
Q2 		– Sell
-206,427
Closed -$7.45M – 70
2025
Q1 		$7.45M Sell
206,427
-254,402
-55% -$9.31M 0.12% 70
2024
Q4 		$16.6M Buy
+460,829
New +$16.2M 0.22% 64

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

RA Capital Management's DRUG Position: Q2 2026 in Review

RA Capital Management held its Bright Minds Biosciences (DRUG) position steady in Q2 2026 at 265,000 shares worth $18.6M. The position accounts for 0.16% of the portfolio, ranked #64.

RA Capital Management first reported a position in DRUG in Q4 2024 and has held it in 4 quarters since. The position peaked at $19.3M in Q1 2026. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • RA Capital Management held 265,000 shares of Bright Minds Biosciences worth $18.6M as of Q2 2026.
  • RA Capital Management left its Bright Minds Biosciences share count unchanged in Q2 2026.
  • Bright Minds Biosciences made up 0.16% of RA Capital Management's portfolio in Q2 2026, its #64 holding.
  • RA Capital Management first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 4 quarters since.
  • RA Capital Management's Bright Minds Biosciences position peaked at $19.3M in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.